Preliminary results of our study suggest that mycophenolate mofetil (MMF) might be a useful treatment in patients who have failed or could not tolerate conventional immunosuppressive therapy for chronic graft-versus-host disease (GVHD). In addition, the favorable toxicity profile and steroid-sparing effect of MMF may be particularly attractive features of this medication.
|Number of pages||3|
|Publication status||Published - Jul 1 2003|
ASJC Scopus subject areas